ABOUT DANAHER LIFE SCIENCES
Every day, scientists around the world are dedicated to unraveling the mysteries of disease, discovering novel therapies and vaccines, and conducting crucial drug testing. At Danaher Life Sciences, a collection of businesses within Danaher Corporation, we play a pivotal role in facilitating these cutting-edge scientific endeavors. Our comprehensive capabilities go beyond research, enabling us to drive the development of innovative biopharmaceuticals, revolutionary cell and gene therapies, and other breakthrough treatments that propel patient health forward and enhance treatment outcomes.


FEATURED ARTICLES
-
Bringing CRISPR therapies to market requires navigating complex global regulations. Learn how strategic planning, risk assessment, and manufacturing alignment can streamline development.
-
Precise genome editing depends on improving HDR efficiency. Learn how guide selection, template design, homology arm optimization, and delivery strategies work together to drive higher-fidelity edits.
-
Sequencing performance can drop quickly with low-quality, low-input FFPE DNA. Gain insight into how one approach helps labs minimize repeats and maintain more consistent results.
-
Synthetic biology is transforming antibody discovery. See how enabling faster screening, greater diversity, and more precise optimization of candidates improves performance and development success.
-
Master the essential DNA cloning workflow, compare key assembly methods, and learn how to optimize sequence design to improve efficiency and achieve more reliable cloning outcomes.
-
Extraction-free qPCR enables faster, lower-cost detection of UTI-associated bacteria directly from urine samples. Explore how this approach simplifies workflows and accelerates time to results.
-
Skip extraction and still achieve reliable qPCR results. See how direct amplification of plant samples enables faster workflows, lower costs, and clear detection of resistance markers.
-
Effective RNA-targeting oligonucleotide design hinges on balancing affinity, stability, and selectivity. Explore how chemical modifications, sequence choices, and delivery approaches influence potency.
-
Genome editing is redefining disease treatment. Advances in CRISPR tools, delivery, and clinical development are accelerating progress from foundational research to real-world therapeutic applications.
-
Simultaneous analysis of HRD, TMB, and MSI offers a more complete view of tumor biology. A modular sequencing approach enables efficient workflows, conserves samples, and delivers deeper insights.
-
Cell-free expression using linear DNA enables rapid protein production without cloning. See how strategic template design improves yield, supporting faster iteration and high-throughput screening.
-
Early TOC excursions often reveal hidden risks in water systems. Capturing samples at the moment of deviation helps teams confirm root causes faster, reduce uncertainty, and maintain control.
-
Accurate TOC results shouldn’t depend on sample order. See how low-level measurements remain reliable even after high-TOC analysis, helping reduce false positives and streamline decisions.
-
AI agents are reshaping biopharma research, offering new ways to analyze data. Find out how success depends on strong data foundations, governance, and thoughtful adoption strategies.
-
Global research teams were generating critical data in disconnected systems, hindering collaboration. Explore how unified workflows and a shared data backbone strengthen efficiency.
-
Biopharma–CRO partnerships often struggle with fragmented communication. Gain insight into how streamlined, automated workflows improve transparency, data quality, and operational speed.
-
Precision medicine is opening new possibilities for IMIDs by moving beyond symptom‑based care. Find out how emerging multi‑omics tools are reshaping how these complex diseases are understood.
-
Long-read sequencing is redefining research by enabling clearer insights into complex genetic regions. Learn how this technology strengthens data confidence and accelerates modern R&D workflows.
-
Growing biotherapeutic complexity demands MS workflows that can unify diverse datasets. Learn how automated approaches enhance data quality, streamline analysis, and support faster development.
-
Mass spectrometry is vital for understanding PTMs in modern biologics. Explore key challenges and how streamlined analysis can reveal deeper, more sensitive insights into biotherapeutic structure.
CONTACT INFORMATION
Danaher Life Sciences
500 Old Connecticut Path
Framingham, MA 01701
UNITED STATES